CURRENT
ISSUE
1599

The FDA has required new warnings in the labels of gabapentin (Neurontin, and others) and pregabalin (Lyrica, Lyrica CR, and generics) about the risk of life-threatening or fatal respiratory depression in patients with respiratory risk factors.1 Respiratory risk factors include chronic obstructive pulmonary disease (COPD) and concurrent use of opioids or other CNS depressants. Elderly patients are also at increased risk.

Gabapentin and pregabalin are...  Continue reading

More from Issue 1599
Previous Issue: 1598      May 18, 2020
Coming Soon
Drugs Past Their Expiration Date
Drugs for Atopic Dermatitis
Meloxicam Injection (Anjeso) for Pain
Dapagloflozin (Farxiga) for Heart Failure
Lumateperone (Caplyta) for Schizophrenia
Search
Donate
Subscribe
Conversation
Follow us   Twitter LinkedIn YouTube Blog RSS   Email Alerts
FROM
ISSUE
1599

A 0.24% ophthalmic solution of the second-generation H1-antihistamine cetirizine (Zerviate – Eyevance) is now available by prescription for treatment of ocular itching associated with allergic conjunctivitis in patients ≥2 years old. Oral cetirizine (Zyrtec, and others), which is used for treatment of allergic conjunctivitis and rhinitis, has been available over the counter (OTC) for years.

STANDARD TREATMENT ... Continue reading

 Tweets